Skip to main content
. 2012 Oct;11(10):1289–1299. doi: 10.1128/EC.00215-12

Table 3.

Occurrence of Upc2 amino acid substitutions in predicted translated sequence in fluconazole-resistant clinical ERG11-overexpressing isolates

Upc2 substitution Isolate Genotype Fluconazole MIC (μg/ml) Expression (fold) of efflux transporter gene (±SE)a
ERG11 CDR1 CDR2 MDR1
G648D 21 Heterozygous 32 6.2 (±0.2) 14.7 (±5.5) 883.3 (±301.9) 10.4 (±3.1)
38 Heterozygous 64 3.8 (±0.3) 3.9 (±0.7) 111.0 (±57.1) 1.4 (±0.2)
47 Heterozygous 128 7.9 (±1.2) 11.8 (±5.1) 327.0 (±166.3) 8.2 (±3.1)
52 Heterozygous 256 3.7 (±1.4) 1.2 (±0.3) 17.1 (±3.2) 0.3 (±0.1)
59 Heterozygous >256 7.2 (±1.0) 6.5 (±0.3) 48.5 (±0.3) 8.0 (±0.2)
71 Heterozygous >256 9.4 (±1.1) 5.6 (±1.9) 149.8 (±56.5) 4.6 (±1.8)
G648S 25 Heterozygous 64 3.6 (±0.6) 1.1 (±0.5) 2.8 (±1.1) 160.5 (±78.9)
35 Heterozygous >256 4.4 (±1.3) 1.2 (±0.4) 0.7 (±0.3) 79.9 (±22.8)
55 Homozygous >256 2.6 (±0.6) 1.7 (±1.5) 26.2 (±17.4) 0.9 (±3.2)
56 Homozygous >256 2.1 (±1.0) 8.0 (±3.1) 167.8 (±94.0) 2.5 (±0.9)
57 Homozygous >256 19.4 (±12.4) 10.2 (±3.5) 263.3 (±106.0) 12.9 (±5.2)
58 Homozygous >256 6.6 (±1.5) 9.7 (±4.2) 226.6 (±131.7) 3.8 (±1.2)
65 Heterozygous >256 4.2 (±0.3) 9.8 (±1.5) 294.9 (±128.4) 2.4 (±0.1)
67 Heterozygous >256 4.7 (±0.7) 7.4 (±2.8) 105.1 (±43.3) 1.2 (±0.5)
69 Heterozygous >256 5.6 (±0.9) 7.2 (±0.5) 136.8 (±69.3) 1.4 (±0.5)
A643T 13 Homozygous 16 2.4 (±1.1) 6.4 (±2.9) 185.9 (±80.9) 2.4 (1.6)
A643V 30 Heterozygous 64 4.6 (±1.6) 1.4 (±0.3) 18.0 (±15.7) 18.9 (±16.7)
68 Heterozygous >256 4.9 (±0.4) 6.3 (±2.2) 64.5 (±31.8) 216.3 (±98.9)
A646V 45 Heterozygous 128 3.5 (±0.3) 4.8 (±0.3) 147.8 (±71.7) 15.5(±7.7)
67 Heterozygous >256 4.7 (±0.7) 7.4 (±2.8) 105.1 (±43.3) 1.2 (±0.5)
Y642F 33 Homozygous 36 12.6 (±1.8) 6.8 (±2.0) 201.5 (±129.0) 1.5 (±0.5)
34 Homozygous 37 7.5 (±0.6) 5.4 (2.5) 126.8 (±62.6) 1.2 (±0.5)
W478C 15 Heterozygous 16 8.1 (±2.7) 15.9 (±3.8) 1415.1 (±400.1) 4.0 (±3.0)
27 Heterozygous 64 6.2 (±2.8) 14.2 (±4.7) 629.7 (±255.3) 1.1 (±0.1)
28 Heterozygous 64 18.1 (±7.3) 18.1 (±6.3) 1439.7 (±570.8) 23.2 (±20.6)
G304R 18 Heterozygous 32 5.6 (±1.2) 10.4 (±2.4) 575.0 (±117.2) 1.0 (±0.3)
19 Heterozygous 32 5.2 (±1.4) 10.0 (±4.8) 401.3 (±204.5) 4.6 (±3.0)
a

qRT-PCR was performed in triplicate.

HHS Vulnerability Disclosure